Published December 7, 2025 | Version v1
Working paper Open

ABORDAGENS TERAPÊUTICAS E PERSPECTIVAS FUTURAS DA IMUNOTERAPIA CAR-NK PARA A ÁREA ONCOLÓGICA: UMA REVISÃO SISTEMÁTICA DE SÍNTESE SEM METANÁLISE (SWIM)

Authors/Creators

  • 1. ROR icon Centro Universitário Cesmac

Description

Esse trabalho foi apresentado em formato de Slide no IV CONAEDUS - Congresso Nacional de Educação e Saúde (Edição 2025).

O presente trabalho foi apresentado pelo pesquisador Leandro Maia Leão nos dias 8, 9 e 10 de outubro de 2025 em ambiente online.

Segue o link para acesso do registro na plataforma ZENODO dos Anais do IV CONAEDUS: https://zenodo.org/records/18275830

DOI: 10.5281/zenodo.18275830

PDF: https://editorahumanize.com/wp-content/uploads/2025/12/ANAIS-IV-CONAEDUS.pdf

Após o termino do evento, o trabalho foi publicado na plataforma Padlet, em seção criada pelo congresso sobre Temas Livre Apresentados, onde encontra-se no início da página, segue o link de acesso direto ao site está aqui: https://padlet.com/jtb2000abreu/conaedus-congresso-nacional-de-educa-o-e-sa-de-dcpppm7u5x57y6qd

Segue também o link de acesso direto ao documento em PDF via plataforma Padlet: https://padlet.com/jtb2000abreu/conaedus-congresso-nacional-de-educa-o-e-sa-de-dcpppm7u5x57y6qd/wish/j40PQDnDGrwPWvXB

  • Currículo Lattes (Brazilian Academic Curriculum): http://lattes.cnpq.br/4285524447816279
  • ORCID: https://orcid.org/0000-0002-8393-687X
  • Contato via E-mail: leandro-maia-@hotmail.com

Files

[RESUMO EXPANDIDO] Abordagens Terapêuticas CAR-NK.pdf

Files (8.4 MB)

Additional details

Identifiers

DOI
10.5281/zenodo.17845738
ISBN
978-65--5255159-7

Related works

Is supplemented by
Book: 10.5281/zenodo.16993584 (DOI)
Working paper: 10.33448/rsd-v14i9.49533 (DOI)
Working paper: 10.33448/rsd-v14i8.49317 (DOI)

Software

Repository URL
https://padlet.com/jtb2000abreu/conaedus-congresso-nacional-de-educa-o-e-sa-de-dcpppm7u5x57y6qd
Programming language
Python
Development Status
Active

References

  • BALKHI, S. et al. CAR-NK cell therapy: promise and challenges in solid tumors. Frontiers in Immunology, v. 16, art. 1574742, 2025.
  • BARDIN, L. Análise de conteúdo. São Paulo: Edições 70, 2016.
  • BASAR, R.; DAHER, M.; REZVANI, K. Next-generation cell therapies: the emerging role of CAR-NK cells. Blood Advances, v. 4, n. 22, p. 5868-5876, 2020.
  • BEXTE, T. et al. Engineering of potent CAR NK cells using non-viral Sleeping Beauty transposition from minimalistic DNA vectors. Molecular Therapy, v. 32, n. 7, p. 2357-2372, 2024.
  • BIEDERSTÄDT, A.; REZVANI, K. Engineering the next generation of CAR-NK immunotherapies. International Journal of Hematology, v. 114, n. 5, p. 554-571, 2021.
  • BURGA, R. A. et al. Engineering the TGFB receptor to Enhance the Therapeutic Potential of Natural Killer Cells as an Immunotherapy for Neuroblastoma. Clinical Cancer Research, v. 25, n. 14, p. 4400-4412, 2019.
  • CAMPBELL, M. et al. Synthesis without meta-analysis (SWIM) in systematic reviews: reporting guideline. BMJ, v. 368, art. l6890, 2020.
  • CHANEY, M. A. So you want to write a narrative review article? Journal of cardiothoracic and vascular anesthesia, v. 35, n. 10, p. 3045–3049, 2021.
  • CORDEIRO, A. M. et al. Revisão sistemática: uma revisão narrativa. Revista do Colegio Brasileiro de Cirurgioes, v. 34, n. 6, p. 428–431, 2007.
  • CURIO, S.; JONSSON, G.; MARINOVIĆ, S. A summary of current NKG2D-based CAR clinical trials. Immunotherapy Advances, v. 1, n. 1, art. ltab018, 2021.
  • DAHER, M.; REZVANI, K. Next generation natural killer cells for cancer immunotherapy: the promise of genetic engineering. Current Opinion in Immunology, v. 51, p. 146-153, 2018.
  • FATE THERAPEUTICS, INC. Anti-ROR1 chimeric antigen receptors (cars), car-nk cells and related methods. Patente No. WO2024073583A1. 2024.
  • GHOBADI, A. et al. Induced pluripotent stem-cell-derived CD19-directed chimeric antigen receptor natural killer cells in B-cell lymphoma: a phase 1, first-in-human trial. The Lancet, v. 405, n. 10473, p. 127-136, 2025.
  • HE, B. et al. Interleukin-21 engineering enhances CD19-specific CAR-NK cell activity against B-cell lymphoma via enriched metabolic pathways. Experimental Hematology & Oncology, v. 14, n. 1, p. 51, 2025.
  • HOSSEINI, M-S. et al. Formulating research questions for evidence-based studies. Journal of medicine, surgery, and public health, v. 2, n. 100046, p. 100046, 2024.
  • HUANG, R. et al. Safety and efficacy of CD33-targeted CAR-NK cell therapy for relapsed/refractory AML. Experimental Hematology & Oncology, v. 14, n. 1, p. 1, 2025.
  • KHORASANI, B. S.; YOUSEFI, A.; BASHASH, D. CAR NK cell therapy in hematologic malignancies and solid tumors; obstacles and strategies to overcome the challenges. International Immunopharmacology, v. 110, art. 109041, 2022.
  • KILGOUR, M. K. et al. Advancements in CAR-NK therapy: lessons to be learned from CAR-T therapy. Frontiers in Immunology, v. 14, art. 1166038, 2023.
  • KRUG, A.; MARTINEZ-TURTOS, A.; VERHOEYEN, E. Importance of T, NK, CAR T and CAR NK Cell Metabolic Fitness for Effective Anti-Cancer Therapy. Cancers, v. 14, n. 1, p. 183, 2021.
  • LEÃO, L. M. et al. Imunoterapia por Receptores de Antígenos Quiméricos (CARs) para células Assassinas Naturais (NK), abordagens terapêuticas e perspectivas futuras na área oncológica: uma revisão sistemática de Síntese Sem Metanálise (SWIM). Research, Society and Development, v. 14, n. 8, p. e0514849317, 2025.
  • LI, T. et al. CAR-NK cells for cancer immunotherapy: recent advances and future directions. Frontiers in Immunology, v. 15, art. 1361194, 2024.
  • LIU, E. et al. Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors. New England Journal of Medicine, v. 382, n. 6, p. 545-553, 2020.
  • LU, S.-J.; FENG, Q. CAR-NK cells from engineered pluripotent stem cells: Off-the-shelf therapeutics for all patients. STEM CELLS Translational Medicine, v. 10, supl. 2, p. S10-S17, 2021.
  • MARIN, D. et al. Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19+ B cell tumors: a phase 1/2 trial. Nature Medicine, v. 30, n. 3, p. 772-784, 2024.
  • MOHER, D. et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS medicine, v. 6, n. 7, p. e1000097, 2009.
  • OUZZANI, M. et al. Rayyan-a web and mobile app for systematic reviews. Systematic reviews, v. 5, n. 1, p. 210, 2016.
  • OWENS, J. K. Systematic reviews: Brief overview of methods, limitations, and resources. Nurse author & editor, v. 31, n. 3–4, p. 69–72, 2021.
  • PAGE, M. J. et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ (Clinical research ed.), v. 372, p. n71, 2021.
  • PARK, H. et al. Efficacy and safety of natural killer cell therapy in patients with solid tumors: a systematic review and meta-analysis. Frontiers in Immunology, v. 15, art. 1454427, 2024.
  • PEREIRA, A. S. et al. Metodologia da pesquisa científica. Santa Maria: UAB/NTE/UFSM, 2018.
  • RAFEI, H.; DAHER, M.; REZVANI, K. Chimeric antigen receptor (CAR) natural killer (NK)-cell therapy: leveraging the power of innate immunity. British Journal of Haematology, v. 193, n. 2, p. 216-230, 2021.
  • SHANGHAI GENE-OPTIMAL BIOTECH. Chimeric antigen receptor and use thereof. Patente No. WO2024250865A1. 2024.
  • UMAN, L. S. Systematic reviews and meta-analyses. Journal of the Canadian Academy of Child and Adolescent Psychiatry, v. 20, n. 1, p. 57-59, 2011.
  • XIA, J.; MINAMINO, S.; KUWABARA, K. CAR-expressing NK cells for cancer therapy: a new hope. Bioscience Trends, v. 14, n. 5, p. 354-359, 2020.
  • YU, Y. et al. Allogenic CD19 CAR NK cells therapy in refractory systemic lupus erythematosus: An open-label, single arm, prospective and interventional clinical trial. ACR Convergence 2024, v. 76, supl. 9, 2024.